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Introduction
Age-related macular degeneration
(AMD) is one of the leading causes
of visual impairment in Western
countries (West 2000). The exudative
form of AMD is associated with high
levels of intravitreal Vascular Endo-
thelial Growth Factor (VEGF). The
ﬁrst intravitreal drug to be used for
exudative AMD was triamcinolone
acetonide. Corticosteroids have been
shown to inhibit VEGF production,
vascular proliferation and vascular
permeability (Nauck et al. 1998; Pen-
fold et al. 2000; Ciulla et al. 2001).
Intravitreal injection of triamcinolone
acetonide (IVTA) results in reduction
in the growth of choroidal neovascu-
larizations (CNVs) when used as sin-
gle therapy (Gillies et al. 2003; Jonas
et al. 2003). Recently approved anti-
VEGF antibodies have shown to be
effective in the treatment of CNV
because of AMD by determining an
average increase of visual acuity, with
a lower complication rate than triam-
cinolone acetonide (Browns Brown
et al. 2009; Kaiser et al. 2007). Peg-
aptanib is an anti-VEGF RNA–based
aptamer that speciﬁcally binds
VEGF165 isoform (Gragoudas et al.
2004). Furthermore, several reports
have described the good safety and
efﬁcacy of intravitreal bevacizumab,
an anti-VEGF drug directed at all
isoforms of VEGF, approved for the
intravenous treatment of metastatic
cancer (Michels et al. 2005; Rosenfeld
et al. 2005) and still used today in
this off-label indication because its
cost is considerably lower than that
of licensed anti-VEGF (Rosenfeld
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ABSTRACT.
Purpose: To evaluate best-corrected visual acuity (BCVA) and foveal thickness (FT)
changes in occult subfoveal choroidal neovascularization (CNV) from age-
related macular degeneration (AMD) after intravitreal bevacizumab (IVB,
1.25 mg ⁄ 0.05 ml), pegaptanib (IVP, 0.3 mg ⁄ 0.09 ml) and triamcinolone acetonide
(IVTA, 4 mg ⁄ 0.1 ml) injected on an as needed basis.
Methods: Retrospective, interventional, comparative study. BCVA (Early Treatment
Diabetic Retinopathy Study LogMAR) and FT by optical coherence tomography
(OCT) were evaluated during 12 months from ﬁrst treatment. Patients were
retreated if signs of neovascular activity were still present on angiography or OCT.
Results: Forty-eight eyes received IVB, 43 eyes received IVP, 52 eyes received
IVTA. BCVA and FT at baseline were 1.22 ± 0.49 LogMAR and 410.2 ±
41.83 lm in the IVB group, 1.25 ± 0.43 LogMAR and 452.3 ± 44.83 lm in the
IVP group and 1.31 ± 0.4 LogMAR and 456.6 ± 48.27 lm in the IVTA group.
BCVA and FT improved in the three groups during follow-up. A signiﬁcantly greater
improvement of BCVA was present at month-3, month-6 and at month-12 in the
IVB and IVP groups (p = 0.01). Improvement of FT was greater in the IVTA
group at month-3 (p = 0.02), while it was greater in the anti-Vascular Endothelial
Growth Factor (VEGF) groups at month-6 and month-12 (p = 0.01). A postopera-
tive increase of intraocular pressure was detected in 9 ⁄ 52 (17.3%) eyes treated with
IVTA, and in two cases it was resistant to topical therapy.
Conclusion: Intravitreal injection of anti-VEGF drugs administered on an as needed
basis for AMD-related occult CNVs provided functional and anatomic improvement
during 12 months of follow-up.
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2006). Herein, we have retrospec-
tively evaluated patients treated with
bevacizumab, pegaptanib and triam-
cinolone on as needed basis for
occult AMD-related choroidal neo-
vascularization.
Methods
The study was approved by the eye
clinic’s ethics committee. The study
was performed in accordance with the
ethical standards laid down in the
1964 Declaration of Helsinki. In a
retrospective comparative study car-
ried out at the Eye Department of
the University Federico II of Naples,
we considered all the eyes with
occult subfoveal CNV treated with
intravitreal bevacizumab, pegaptanib
or triamcinolone acetonide between
December 2005 and April 2008. Mini-
mally classic CNVs, classic CNVs, ret-
inal angiomatous proliferation and
polypoidal choroidal vasculopathy
were excluded by analysis of ﬂuores-
cein angiography and indocyanine
green angiography. Eyes with open
angle glaucoma and an intraocular
pressure (IOP) greater than 22 mmHg
were also excluded from the study.
Treatment was performed with intra-
vitreal injection of bevacizumab, peg-
aptanib or triamcinolone. IVTA was
administered between December 2005
and April 2006 because the use of
anti-VEGF drugs for neovascular
AMD was not yet widespread. Bev-
acizumab was administered between
December 2005 and November 2007 as
it was the only anti-VEGF drug avail-
able at our hospital during that period.
Between December 2005 and April
2006, triamcinolone and bevacizumab
were used randomly by different sur-
geons. Pegaptanib was administered
between November 2007 and April
2008. The changeover to pegaptanib
was because of its licensed status
when compared to bevacizumab. When
bevacizumab and triamcinolone were
used for injection, each patient was
informed of their off-label status
and informed consent was obtained.
Bevacizumab (0.05 ml solution pre-
pared from Avastin 100 mg ⁄ 4 ml vial;
Roche, Switzerland), pegaptanib (0.3
mg ⁄0.09 ml, Macugen; Eye Tech ⁄
Pﬁzer, New York, NY, USA) or
triamcinolone acetonide (4 mg ⁄ 0.1 ml;
Kenacort-A; Bristol-Myers Squibb,
Sermoneta, Latina, Italy) were admin-
istered intravitreally through the pars
plana according to standard proce-
dures (Jonas et al. 2003). Patients were
retreated during follow-up if vascular
leakage was still present on angiogra-
phy or intraretinal ﬂuid or subretinal
ﬂuid was detected by optical coherence
tomography (OCT). Bevacizumab and
pegaptanib were readministered after
at least 1 month from previous injec-
tion, while minimum time before
retreatment for IVTA was 4 months.
Data collection included the history
of any treatment for AMD in the
study eye, Early Treatment Diabetic
Retinopathy Study (ETDRS) Log-
MAR best-corrected visual acuity
(BCVA) testing, slit lamp examination
of the anterior segment, IOP measure-
ment and dilated fundus examination.
At each visit, mean thickness in the
central 1000-lm diameter area (foveal
thickness, FT) was measured using
optical coherence tomography (Stra-
tus OCT, Version 4.0.1; Carl Zeiss
Meditec, Dublin, CA, USA). High-
resolution Radial Line scan protocol
(1.0 B scans ⁄ second, 512 axial mea-
surements with a resolution of around
10 microns) was used. The inner and
outer retinal boundaries for measure-
ment of FT were deﬁned automati-
cally by the computer software.
Patients were observed at baseline and
monthly with retreatment based on
disease activity. Fluorescein angio-
graphy and indocyanine green angio-
graphy were performed at baseline, at
month-3, at month-6, at month-12
and in case of BCVA reduction. Data
at baseline, month-3, month-6 and
month-12 were collected. Adverse
effects considered during follow-up
were raised intraocular pressure,
development of cataract, ocular toxicity
or uveitis, retinal pigment epithelial
tear, endophthalmitis, rhegmatog enous
retinal detachment, systemic adverse
events such as thrombosis or hyper-
tension.
Statistical analysis was performed
using the Statistical Package for Social
Sciences (version 17.0; SPSS Inc., Chi-
cago, IL, USA). Intragroup changes
were compared by repeated measures
anova with Dunnett correction for
multiple comparisons. The differences
in the results between the three groups
were compared by means of the
Mann–Whitney U-test. Spearman cor-
relation was used to evaluate correla-
tion between anatomic and functional
changes. The level of statistical signiﬁ-
cance was set at p < 0.05. Data are
presented as means ± standard devia-
tion.
Results
Data about characteristics of the two
groups at baseline are resumed in
Table 1. In the bevacizumab (IVB)
group, there were 48 eyes (48 patients,
26 women, 22 men, mean age 75.5 ±
6.8 years). In the pegaptanib (IVP)
group, there were 43 eyes (43 patients,
20 women, 23 men, mean age 77.2 ±
7.1 years). In the triamcinolone group,
there were 52 eyes (52 patients, 27
women, 25 men, mean age 76.2 ±
5.8 years). Mean BCVA and FT were
1.22 ± 0.49 LogMAR and 410.2 ±
Table 1. Characteristics of the study groups at baseline.
IVB IVP IVTA p
n eyes (patients) 48 (48) 43 (43) 52 (52) 0.1
Male ⁄Female (% ⁄%) 22 ⁄ 26 (45.9 ⁄ 54.1) 23 ⁄ 20 (53.5 ⁄ 46.5) 25 ⁄ 27 (48.1 ⁄ 51.9) 0.08
Age (years, Mean ± SD) 75.5 ± 6.8 77.2 ± 7.1 76.2 ± 5.8 0.7
LogMAR BCVA (Mean ± SD) 1.22 ± 0.49 1.25 ± 0.43 1.31 ± 0.4 0.08
FT (lm, Mean ± SD) 410.2 ± 41.83 452.3 ± 44.83 456.6 ± 48.27 0.07
Previous PDT (cases) 7 (14.5%) 5 (11.6%) 9 (17.3%) 0.1
Time from last PDT (months, Mean ± SD) 6.2 ± 3.2 5.3 ± 2.1 6.8 ± 2.2 0.1
IVB = intravitreal bevacizumab; IVP = intravitreal pegaptanib; IVTA = intravitreal triamcinolone; SD = standard deviation; BCVA = best-
corrected visual acuity; FT = foveal thickness; lm = microns; PDT = photodynamic therapy.
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41.83 lm in the IVB group, 1.25 ±
0.43 LogMAR and 452.3 ± 44.83 lm
in the IVP group, 1.31 ± 0.4 Log-
MAR and 456.6 ± 48.27 lm in the
IVTA group. No signiﬁcant differ-
ences were present at baseline among
the three groups as concerns number
of eyes, age, BCVA and FT.
Full ﬂuence photodynamic therapy
(PDT) had been administered in seven
cases (14.5%) 6.2 ± 3.2 months prior
to IVB, in ﬁve cases (11.6%) 5.3 ±
2.1 months before IVP and in nine
cases (17.3%) 6.8 ± 2.2 months
before IVTA. No difference as con-
cerns the number of PDT treatments
prior to anti-VEGF treatment (p =
0.01) and time from last PDT treat-
ment (p = 0.01) was present among
the three groups.
Mean number of injections during
12 months after ﬁrst treatment was
4.3 ± 0.4 in the IVB group,
4.1 ± 0.2 in the IVP group and
3.2 ± 0.2 in the IVTA group. All
patients completed the 12 months fol-
low-up. During follow-up, no patient
was treated with drugs other than the
one used for the initial treatment. No
signiﬁcant differences were present
between the IVB and the IVP groups
as concerns the number of injections,
while the number of injections in the
IVTA group was signiﬁcantly lower
(p = 0.02) because of the longer time
before retreatment in this group.
A signiﬁcant improvement of
BCVA was present in the bev-
acizumab group and in the pegaptanib
group at month-3 (0.81 ± 0.3 Log-
MAR, p = 0.05 and 0.80 ± 0.44
LogMAR, p = 0.04, respectively),
month-6 (0.61 ± 0.21LogMAR, p =
0.005 and 0.81 ± 0.43 LogMAR,
p = 0.03, respectively) and month-12
(0.65 ± 0.4 LogMAR, p = 0.005 and
0.83 ± 0.44 LogMAR, p = 0.03,
respectively) (Fig. 1). In the IVTA
group, a nonsigniﬁcant improvement
of BCVA was present at month-3
(1.20 ± 0.11 LogMAR, p = 0.2),
month-6 (1.03 ± 0.29 LogMAR,
p = 0.07) and month-12 (1.08 ± 0.32
LogMAR, p = 0.08). In the IVB and
in the IVP group, no patient showed
a worsening in BCVA, while in the
triamcinolone group 8 ⁄ 52 patients
(15.3%) experienced a visual loss of
0.2 ± 0.09 LogMAR at month-3,
0.17 ± 0.07 LogMAR at month-6 and
0.19 ± 0.08 LogMAR at month-12.
At month-3, month-6 and month-12
improvement in BCVA was signiﬁ-
cantly greater after IVB than after
IVTA (p = 0.01), as was greater after
IVP than after IVTA (p = 0.01). No
signiﬁcant differences in BCVA change
were present after IVB and IVP at
month-3 (p = 0.08), month-6 (p =
0.07) and month-12 (p = 0.07). No
signiﬁcant differences in BCVA change
were present between eyes with prior
PDT and treatment-naı¨ve eyes.
As concerns FT, a signiﬁcant
improvement was present in both IVB
and IVP groups at month-3 (316.2 ±
25.16, p < 0.001 and 340.4 ± 10.70,
p < 0.001, respectively), month-6
(230.2 ± 11, p < 0.001 and 264.5 ±
12.35, p < 0.001, respectively) and
month-12 (233.1 ± 18, p < 0.001 and
274.3 ± 13.33, p < 0.001, respectively)
(Fig. 1). The IVTA group showed an
improvement that was signiﬁcant at
month-3 (248.3 ± 26.20, p = 0.005),
but not at month-6 (398.7 ± 36.74,
p = 0.1) and at month-12 (373.5±
28.22, p = 0.1). At month-3, the FT
improvement in the IVTA group
()45.6%) was greater than in the IVB
and IVP groups ()22.9% and )24.7,
respectively) (p = 0.02). At month-6
and at month-12, the anti-VEGF
groups experienced a signiﬁcantly
greater improvement of FT (p =
0.01). Correlation between BCVA and
FT change was 0.33 (Spearman rho,
p = 0.001) in IVB group, 0.26 in IVP
group (p = 0.02) and 0.31 (p = 0.001)
in the IVTA group. Eyes with prior
PDT did not signiﬁcantly differ from
treatment-naı¨ve eyes as concerns FT.
A detachment of the pigment epi-
thelium was present at baseline in
21 ⁄ 48 (43.7%) eyes treated with
bevacizumab, in 17 ⁄ 43 (39.5%) eyes
treated with pegaptanib and in 30 ⁄52
(57.6%) eyes treated with triamcino-
lone. IVB lead to resolution of the
PED in 8 ⁄ 21 (38%) eyes and was
more effective than IVP (5 ⁄ 17 cases,
29.4%, p = 0.005) and IVTA (6 ⁄ 30
eyes, 20%, p < 0.001). Also IVP was
signiﬁcantly more effective than IVTA
(p < 0.001). No tears of the pig-
ment epithelium were detected in any
group during follow-up. Among cases
(A) (B)
Fig. 1. Change of (A) best-corrected visual acuity (BCVA, ETDRS LogMAR) and (B) foveal thickness (FT) during 12 months in the three
groups (means and 95% conﬁdence interval). IVTA = intravitreal triamcinolone acetonide; IVB = intravitreal bevacizumab; IVP = intravitreal
pegaptanib; *p < 0.05.
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with PED at baseline, visual acuity at
12-month visit had improved in 12 ⁄ 68
cases (17.6%), was stable in 43 ⁄ 68
cases (63.2%) and worsened in 13 ⁄ 68
eyes (19.1%).
A reduction of the intraretinal
oedema and subretinal ﬂuid was pres-
ent in the three groups. Although
reduced, after 3 months subretinal
ﬂuid was still persistent in 12 ⁄ 52
(23%) eyes treated with IVTA, in
11 ⁄48 (22.9%) eyes treated with IVB
and in 11 ⁄ 43 (25.5%) eyes treated
with IVP. After 6 months, subretinal
ﬂuid was persistent in 27 ⁄ 52 (51.9%)
eyes treated with IVTA, in 6 ⁄ 48
(12.5%) eyes treated with IVB and in
7 ⁄ 43 (16.2%) eyes treated with IVP.
After 12 months, subretinal ﬂuid per-
sisted in 16 ⁄ 52 (30.7%) eyes treated
with IVTA, in 5 ⁄ 48 (10.4%) eyes trea-
ted with IVB and in 7 ⁄ 43 (16.2%)
eyes treated with IVP.
No side-effects were present in the
IVB and IVP groups. A postoper-
ative increase of IOP >23 mmHg was
detected in 9 ⁄ 52 (17.3%) eyes treated
with IVTA. In 7 ⁄ 9 cases, IOP was low-
ered to values <21 mmHg with topi-
cal antiglaucomatous treatment after a
mean period of 5.6 ± 1.4 months. In
2 ⁄ 9 cases, glaucoma ﬁltration surgery
was necessary to reduce IOP.
Discussion
To our knowledge, this is the ﬁrst
reported comparative evaluation of
intravitreal injection of bevacizumab,
pegaptanib and triamcinolone aceto-
nide for AMD-related occult CNVs.
A signiﬁcant improvement in
BCVA was present in the IVB and
IVP groups during 12 months. At 12-
month visit, BCVA had improved by
0.55 LogMAR in the IVB group and
by 0.42 LogMAR in the IVP group.
Our results agree with the signiﬁcant
0.37 LogMAR improvement in BCVA
recently reported for occult CNVs
during 12 months after treatment with
intravitreal bevacizumab (Costagliola
et al. 2009). As concerns treatment
with pegaptanib, recent studies have
reported a signiﬁcant 0.10 LogMAR
improvement after 9.1 months (Qui-
ram et al. 2007) and a signiﬁcant
0.28 LogMAR improvement after
12 months (Sivaprasad et al. 2008). In
the IVTA group, a BCVA improve-
ment was present, but not signiﬁcant.
In the IVTA group, the improvement
of FT at month-3 was statistically
greater, while at month-6 and month-
12 only the anti-VEGF groups
showed a persistent and signiﬁcant
improvement. The effectiveness of
intravitreal triamcinolone in reducing
retinal oedema has been previously
reported (Steen et al. 1998; Jonas &
Sofker 2001; Sutter et al. 2004), but
no beneﬁcial effect have been shown
on eyes with minimally classic or
occult CNV secondary to AMD
(Jonas et al. 2006; Lee et al. 2007).
The differences in visual outcome
between eyes treated with triamcino-
lone and eyes treated with anti-VEGF
drugs may be explained by the fact
that anti-VEGF drugs have a stronger
anti-angiogenic effect than IVTA
(Jonas et al. 2009). The low correla-
tion found in our study between ana-
tomic and functional effects of IVTA
during follow-up agrees with previ-
ously reported studies about the use
of IVTA in exudative AMD (Gillies &
Larsson 2007) and diabetic retinopa-
thy (Larsson et al. 2005), and suggests
a role of factors other than retinal
oedema on visual recovery, such as
the function of the retinal pigment
epithelium and its relationship to the
photoreceptors (Gillies et al. 2003).
The main anatomic effect of the
three intravitreal drugs was the reduc-
tion of the intraretinal oedema, which
improved in the three groups. PED
persisted after treatment in most cases,
while subretinal ﬂuid improved at
month-3 in the three groups and
greatly worsened during following
months in the IVTA group. Foveal
thickness showed a greater improve-
ment in the IVTA group at month-3,
mainly because of the reduction of int-
raretinal oedema, although a similarly
greater improvement of visual acuity
was not present. The low correlation
between BCVA and FT has been
reported already (Spaide et al. 2006).
The resolution of the PED was
obtained in 38% of the eyes treated
with bevacizumab and in 29.4% of
the eyes treated with pegaptanib. The
low responsiveness of the PED to in-
travitreal anti-VEGF has been already
reported (Atmani et al. 2009; Furino
et al. 2009). As also suggested by our
data, pegaptanib has shown less effec-
tiveness than bevacizumab in reducing
PED height in retrospective large ser-
ies, probably because of its lower
effectiveness in reducing vascular per-
meability (Lommatzsch et al. 2009).
Of 68 eyes with PED at baseline,
BCVA at 12-month visit only
improved in 17.6% and remained sta-
ble in 63.2% of cases. These data
agree with previous ﬁndings by
Atmani et al. (2009), who suggested
CNV lesions associated with PED to
be a severe form of neovascular AMD
less responsive to treatment.
No tears of the pigment epithelium
were detected in any group during
12 months of follow-up. Tears of the
retinal pigment epithelium have been
reported after intravitreal anti-VEGF
with an incidence ranging from 0.06%
to 12.5% (Fung et al. 2006; Garg
et al. 2008; Wong et al. 2008; Gelisken
et al. 2009). The absence of such a
complication in our series could be
explained by the relatively short mean
follow-up.
No signiﬁcant difference in the
number of injections was noted
between the IVB and IVP groups,
while comparison with the IVTA
group was not possible because of the
different minimum time for retreat-
ment. Off-label use of intravitreal bev-
acizumab has been shown to
signiﬁcantly improve vision in several
studies (Avery et al. 2006; Rich et al.
2006; Spaide et al. 2006). In a recent
prospective study, intravitreal pegap-
tanib provided good long-term results
in predominantly and pure occult
CNVs (79% responders, 43% main-
tainers, and 9% gainers at 52 weeks
after eight injections) (Atmani et al.
2009). In the Vascular Endothelial
Growth Factor Inhibition Study in
Ocular Neovascularization (VISION)
trial, 6% of patients receiving pegap-
tanib for CNV lesions of all angio-
graphic subtypes showed signiﬁcant
visual improvement compared with
2% of sham-treated controls (Gragoudas
et al. 2004). Anti-VEGF agents decrease
the plasma leak through incompetent
neovascularization and result in a
temporary increase in vision. They
often require frequent intravitreal
injections, which carry the risks of ret-
inal tear and endophthalmitis (van
Wijngaarden et al. 2005). In our
study, retreatment was performed on
an as needed basis, and an overall
functional and anatomic improvement
was obtained. VEGF is required for
the maintenance of physiological vas-
cular structures, and a reduction in
choriocapillary fenestration was recently
Acta Ophthalmologica 2010
e308
reported following anti-VEGF therapy
(Peters et al. 2007). A retreatment
strategy based on the disease activity
seems advisable to ensure that as
much as needed (but as little as possi-
ble) VEGF inhibition is induced.
Although according to reported
suggestions IVTA was reinjected after
at least 4 months (Gillies et al. 2003),
a postoperative increase in IOP was
detected in nine cases treated with in-
travitreal triamcinolone (17.3%) and
was resistant to topical antiglaucoma-
tous treatment in two cases. The local
and systemic safety of intravitreal
anti-VEGF has been previously
described (Aiello et al. 2004; Noma
et al. 2008), while corticosteroids often
determine cataract formation and ele-
vation of IOP (Armaly 1965; Butcher
et al. 1994).
In our study, no signiﬁcant differ-
ence in the number of prior visudyne
PDT treatments was found among the
three groups. The lack of efﬁcacy of
PDT with verteporﬁn in patients with
occult CNV lesions was recently con-
ﬁrmed in the Visudyne in Occult
(VIO) trial (Kaiser et al. 2009), while
the VISION trial demonstrated the
safety and efﬁcacy of VEGF inhibi-
tors in all types of neovascular AMD
(Gragoudas et al. 2004). However, the
inﬂuence of any prior treatment on
the outcome of anti-VEGF injection is
controversial. As the evaluation of
previously treated and treatment-naive
patients showed similar outcomes in
vision improvement and FT reduction
(Goff et al. 2007; Leydolt et al. 2010),
our results could be extended to treat-
ment-naı¨ve patients.
Nowadays, anti-angiogenic intravi-
treal treatment is a mainstay for all
lesion subtypes in neovascular AMD.
Combined treatment with steroids and
PDT has shown promising results
mostly as concerns the reduction of re-
treatment rates (Augustin & Schmidt-
Erfurth 2006). Emerging strategies
include RNA interference, anti-VEGF
Trap, blockage of tyrosine kinase
cascade, RPE-derived factor-based ther-
apies, nicotinic acetylcholine receptor
antagonists, immunosuppressant sirol-
imus and gene therapy, which are
currently under study.
In conclusion, intravitreal bev-
acizumab, pegaptanib and triamcino-
lone injected on an as needed basis for
AMD-related occult CNVs provided
improvement of BCVA and FT during
12 months of follow-up. Better visual
and anatomic outcome was observed
in eyes treated with bevacizumab and
pegaptanib, while IVTA was associ-
ated with a higher risk of IOP
increase. Therefore, anti-VEGF drugs
should be considered as a mainstay for
treatment of occult CNVs, while treat-
ment with IVTA should not be used
because of its side-effects.
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